Notes
The study was supported by funds from Novo Nordisk, Søborg, Denmark.
Reference
Poehlmann J, et al. Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy. ClinicoEconomics and Outcomes Research : 7 Oct 2019. Available from: URL: https://doi.org/10.2147/CEOR.S218746
Rights and permissions
About this article
Cite this article
Insulin degludec/liraglutide "good value for money" in T2DM in Italy. PharmacoEcon Outcomes News 839, 23 (2019). https://doi.org/10.1007/s40274-019-6304-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6304-9